These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 5675486)

  • 21. Dopamine and dopamine metabolites in Parkinson's disease-a review.
    Barbeau A
    Proc Aust Assoc Neurol; 1968; 5(1):95-100. PubMed ID: 4885282
    [No Abstract]   [Full Text] [Related]  

  • 22. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen and Parkinson's disease.
    Horstink MW; Strijks E; Dluzen DE
    Adv Neurol; 2003; 91():107-14. PubMed ID: 12442669
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa delivery systems for the treatment of Parkinson's disease: an overview.
    Goole J; Amighi K
    Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF GABA levels in Parkinson's disease.
    de Jong PJ; Lakke JP; Teelken AW
    Adv Neurol; 1984; 40():427-30. PubMed ID: 6695622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parkinson disease and the neuronal dopamine uptake complex].
    Costentin J
    Ann Pharm Fr; 1995; 53(4):145-54. PubMed ID: 7574268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
    Nyholm D
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of Parkinson's disease.
    Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
    [No Abstract]   [Full Text] [Related]  

  • 30. Toxic effects of dopamine metabolism in Parkinson's disease.
    Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 32. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.
    Evans AH; Katzenschlager R; Paviour D; O'Sullivan JD; Appel S; Lawrence AD; Lees AJ
    Mov Disord; 2004 Apr; 19(4):397-405. PubMed ID: 15077237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
    Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 38. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
    [No Abstract]   [Full Text] [Related]  

  • 40. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
    Zhu BT
    Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.